The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
Abstract
PURPOSE: A phase II study that alternates the sequence of chemotherapy (carmustine [BCNU], cisplatin [CDDP], and dacarbazine [DTIC]) and biologic therapy (interleukin-2 [IL-2] and interferon alfa-2 alpha [alpha IFN]) was performed to establish a safe and efficacious way to sequence these forms of treatment for metastatic melanoma. PATIENTS AND METHODS: Patients who had measurable metastatic melanoma, a Karnofsky performance status of greater than or equal to 70, and no clinically significant cardiac or pulmonary dysfunction were eligible for entry onto this trial. Responses to treatment were assessed after a treatment cycle by two tumor evaluations at least 4 weeks apart. RESULTS: Forty-two consecutive patients with metastatic melanoma were treated with this sequential chemoimmunotherapy. Transient thrombocytopenia and neutropenia were observed frequently, but neither hemorrhage nor infection occurred in any of the patients. Of the 42 patients, 10 achieved a complete response (24%), 14 achieved a partial response (33%), two achieved a minor response (5%), eight had stable disease (19%), and eight (19%) had progressive disease. The median time to disease progression for all patients was 7 months. The median survival for all patients entered onto the trial was 11.5 months. A vitiligo-like depigmentation was induced in many patients by this treatment. CONCLUSIONS: Cytotoxic chemotherapy can be administered safely immediately before or immediately after IL-2 and alpha IFN. Sequential chemoimmunotherapy administered as previously described yields a response rate of more than 55%. The overall survival curve suggests that a proportion of patients may achieve a long-term benefit from this treatment. Also, cutaneous depigmentation induced by this treatment suggests that immune modulation may contribute to the antimelanoma effect of this treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S., & White, D. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1863 · Cited by 374
Vitiligo in patients with metastatic melanoma: A good prognostic sign
Nordlund, J. J., Kirkwood, J. M., Forget, B. M., Milton, G., Albert, D. M., & Lerner, A. B. (1983) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(83)70182-9 · Cited by 288
Antibodies to normal human melanocytes in vitiligo.
Naughton, G. K., Eisinger, M., & Bystryn, J. C. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.1.246 · Cited by 216
Darrow, T. L., Slingluff, C. L., & Seigler, H. F. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.9.3329 · Cited by 214
Norris, D. A., Kissinger, R. M., Naughton, G. M., & Bystryn, J. C. (1988) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12461505 · Cited by 205
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.
Parkinson, D. R., Abrams, J. S., Wiernik, P. H., Rayner, A. A., Margolin, K. A., Van Echo, D. A., Sznol, M., Dutcher, J. P., Aronson, F. R., & Doroshow, J. H. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.10.1650 · Cited by 198
Thyroiditis after treatment with interleukin-2 and interferon α-2a
Pichert, G., Jost, L. M., Zöbeli, L., Odermatt, B., Pedia, G., & Stahel, R. A. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.237 · Cited by 72
Effective chemotherapy for melanoma after treatment with interleukin-2
Richards, J. M., Gilewski, T. A., Ramming, K., Mitchel, B., Doane, L. L., & Vogelzang, N. J. (1992) · Cancer · Cited by 54
Self-citationPhase I Study of Weekly 24-hour Infusions of Recombinant Human Interleukin-22
Richards, J. M., Barker, E., Latta, J., Ramming, K. P., & Vogelzang, N. J. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.16.1325 · Cited by 30
Self-citation
Cited by
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,092
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
Pisha, E., Chai, H., Lee, I.-S., Chagwedera, T. E., Farnsworth, N. R., Cordell, G. A., Beecher, C. W. W., Fong, H. H. S., Kinghorn, A. D., Brown, D. M., et al. (1995) · Nature Medicine · doi:10.1038/nm1095-1046 · Cited by 886
Human tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
Metadata
- Authors
- Richards, J. M., Mehta, N., Ramming, K., & Skosey, P.
- Venue
- Journal of Clinical Oncology
- Published
- 1992-08
- Volume
- 10
- Issue
- 8
- Pages
- 1338-1343
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1888862664
- Cited by
- 257
- References
- 10
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. https://app.cochat.ai/papers/10.1200/jco.1992.10.8.1338
- The paper
- Richards, J. M., Mehta, N., Ramming, K., & Skosey, P. (1992). Sequential chemoimmunotherapy in the treatment of metastatic melanoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1992.10.8.1338
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.